How many insider trades does FilingIQ track for RGNX?

FilingIQ tracks 697 Form 4 insider transactions for RGNX (REGENXBIO Inc.), covering filings from Oct 14, 2015 onwards. 2 of those were filed in the last 90 days.

Are RGNX insiders net buyers or net sellers?

Across the full Form 4 history for RGNX, 0 transactions (0%) were open-market purchases and 371 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does RGNX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is RGNX in?

REGENXBIO Inc. (RGNX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $414.60M.

RGNX insider trading

NasdaqGS Healthcare

REGENXBIO Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

697

Last 90 days

Buys / sells

0% / 53%

Market cap

$414.60M

About REGENXBIO Inc.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Company website: www.regenxbio.com

RGNX insider activity at a glance

FilingIQ has scored 697 insider transactions for RGNX since Oct 14, 2015. The most recent filing in our index is dated May 11, 2026.

Across the full history, 0 open-market purchases and 371 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on RGNX insider trades is 50.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live RGNX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for RGNX?: FilingIQ tracks 697 Form 4 insider transactions for RGNX (REGENXBIO Inc.), covering filings from Oct 14, 2015 onwards. 2 of those were filed in the last 90 days.
Are RGNX insiders net buyers or net sellers?: Across the full Form 4 history for RGNX, 0 transactions (0%) were open-market purchases and 371 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does RGNX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is RGNX in?: REGENXBIO Inc. (RGNX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $414.60M.

Methodology & sources

Every RGNX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.